ARENA PHARMAC (NASDAQ:ARNA)

View All ReportsStreetInsider.com Reports on ARNA

Feb 4, 2010 07:39 AM Rodman & Renshaw Upgrades Arena Pharmaceutical (ARNA) to Market Perform

Dec 23, 2009 05:30 PM After-Hours Movers 12/23: MRM, BQI, SLGN Higher; ARNA Lower

Dec 23, 2009 04:09 PM Arena Pharma (ARNA) Announces Merck (MRK) Discontinues Development of MK-1903

Dec 22, 2009 08:07 AM Arena Pharmaceuticals (ARNA) Submits New Drug Application to FDA for Lorcaserin

Dec 17, 2009 10:51 AM Notable Analyst Rating Changes 12/17: NWSA, UNM, LNC, PTV Upgraded; ADP, AEM, FGXI, OC Downgrades

View All Press ReleasesCompany Press Releases on ARNA

Feb 8, 2010 06:50AM Pharmaceutical Stock Alert Arena Pharmaceuticals Issued by Beacon Equity

Feb 4, 2010 08:00AM Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

Jan 4, 2010 08:00AM Arena Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

Dec 23, 2009 04:05PM Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis

Dec 22, 2009 08:00AM Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management

StreetInsider Reports on ARNA by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on ARNA

Jan 4, 2010 05:30 AM Pfizer Discontinues Cancer Drug: Biotech's Recently Missed Targets

Nov 10, 2009 03:07 PM Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript

Nov 10, 2009 07:19 AM Wall Street Breakfast: Must-Know News

Nov 4, 2009 09:55 AM Options Trader: Wednesday Outlook, Fed Edition

Nov 3, 2009 11:14 AM Amylin Takes Lead in Obesity Race

View All FilingsSEC Filings on ARNA

Feb 1, 2010 03:24PM Form SC 13G/A ARENA PHARMACEUTICALS Filed by: OPPENHEIMER FUNDS INC

Jan 29, 2010 02:15PM Form SC 13G ARENA PHARMACEUTICALS Filed by: BlackRock Inc.

Jan 28, 2010 05:56PM Form 4 ARENA PHARMACEUTICALS For: Jan 28 Filed by: BEHAN DOMINIC P

Jan 27, 2010 04:11PM Form 8-K ARENA PHARMACEUTICALS For: Jan 22

Jan 11, 2010 09:32AM Form SC 13G/A ARENA PHARMACEUTICALS Filed by: FEDERATED INVESTORS INC /PA/

Comments on recent ARNA articles

ghdhairirons
on Dec 23, 2009
at 08:58 PM ghdhairirons http://www.ghdhairirons.com/ ghd hair straighteners are in best design. http://www.discountukghd.com/ghd-pure-white-limited-edition-hair-straightenersiv-styler-mk4-p-41.html ghd pure white is 63% off, http://www.discountukghd.com/ghd-purple-limited-edition-hair-straighteners-iv-styler-mk4-p-42.html ghd purple is only $90.http://www.ghdhairirons.com/ ghd hair straighteners are in best design. http://www.discountukghd.com/ghd-pure-white-limited-edition-hair-straightenersiv-styler-mk4-p-41.html ghd pure white is 63% off, http://www.discountukghd.com/ghd-purple-limited-edition-hair-straighteners-iv-styler-mk4-p-42.html ghd purple is only $90.
Article: After-Hours Movers 12/23: MRM, BQI, SLGN Higher; ARNA Lower

chris
on Mar 17, 2009
at 02:08 AM SEC The SEC doesnt investigate. They are only a cleanup crew. Witness B Maddoff, who, despite hundreds of tips over 5 years, was not turned in until the economy tanked.
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

JAC47
on Mar 16, 2009
at 06:12 PM ARNA Analysis The Canaccord analysist must have missed the ARNA business presentation slide 54 (December 2008) below. The FDA required the first phase III Bloom Trial to exclude those with Valvulopathy. However, the FDA allowed patients with existing valvulopathy in the Second pahse III Blossum Trial. They would not have done that if there was any significant signs of risk in the Bloom Trial. Bad call by an analyst with a BA in economics. • BLOOM – 3,182 patients randomized 1:1 during Year 1 to receive placebo or lorcaserin 10 mg BID – Echoes performed at Screening, 6, 12, 18 and 24 months – Patients with FDA valvulopathy excluded – Echo-DSMB reviewed all echoes from 6 and 12 months (unblinded)— differences, if any, between placebo and lorcaserin group were not meaningful • BLOSSOM – 4,008 patients randomized 2:1:2, placebo: lorcaserin 10 mg QD: lorcaserin 10 mg BID – Echoes performed at Baseline, 6 and 12 months – No echo exclusion criteria; FDA valvulopathy allowed – Data will be combined with BLOOM data for integrated analysis with sufficient statistical power to address negotiated endpoint
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

wasl
on Mar 16, 2009
at 02:07 PM ARNA This is the broker that obviously is behind the dubious naked shorts, should be investigated by sec!
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

Comments on ARNA

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?